Biotech Intercept Pharmaceuticals (ICPT) announced Tuesday that it had hammered out a design for a phase three trial of its nonalcoholic steatohepatitis (NASH) treatment, but the stock sold off as the time frame looked longer than many investors expected. There’s no current treatment for NASH, a slow-acting disease in which fat buildup around the liver causes progressive scarring, which is why there was no previous model of a large clinical trial
Biotech Intercept Pharmaceuticals (ICPT) spiked more than 9% to near 285 Thursday afternoon when a competitor’s clinical trial produced ambiguous results. GenFit, a French biotech that doesn’t trade in the U.S., announced that its drug GFT505 had failed to meet its primary endpoint in non-alcoholic steatohepatitis (NASH), a form of liver damage caused by accumulation of fat. Progress was measured by performing a liver biopsy at the beginning and
Biotech FibroGen (FGEN) jumped 23% Monday to 33.83, a new high for a stock that went public at 18 on Nov. 13. FibroGen stock rose along with several other players in the liver-disease field, including Intercept Pharmaceuticals (ICPT), Conatus (CNAT) and Raptor Pharmaceuticals (RPTP), after the journal Hepatology published the results of a workshop between the FDA and the American Association for the Study of Liver Disease (AASLD), which laid out